Myofibroblast‐Specific Msi2 Knockout Inhibits HCC Progression in a Mouse Model
Chen Qu,Lu He,Nan Yao,Jinying Li,Yuchuan Jiang,Binkui Li,Shuang Peng,Kunpeng Hu,Dong Chen,Guo Chen,Wei Huang,Mingrong Cao,Jun Fan,Yunfei Yuan,Wencai Ye,Jian Hong
DOI: https://doi.org/10.1002/hep.31754
IF: 17.298
2021-07-01
Hepatology
Abstract:<section class="article-section__content"><p>Myofibroblasts play a pivotal role in the development and progression of hepatocellular carcinoma (HCC). Here, we aimed to explore the role and mechanism of myofibroblast Musashi RNA binding protein 2 (MSI2) in HCC progression. Myofibroblast infiltration and collagen deposition were detected and assessed in the tissues from 117 HCC patients. Transgenic mice (<i>Msi2<sup>ΔCol1a1</sup></i>) with floxed <i>Msi2</i> allele and Col1a1‐CreER were constructed to generate a myofibroblast‐specific <i>Msi2</i> knockout model. Mouse HCC cells were orthotopically transplanted into the <i>Msi2<sup>ΔCol1a1</sup></i> or the control mice (<i>Msi2<sup>F/F</sup></i>). We found that the deposition of collagen fibers, the main product of myofibroblasts, predicted a poor prognosis for HCC; meanwhile, we detected high MSI2 expression in the peritumoral infiltrated myofibroblasts. Conditional deletion of <i>Msi2</i> in myofibroblasts significantly inhibited the growth of orthotopically implanted HCC, reduced both intrahepatic and lung metastasis, and prolonged the overall survival of tumor‐bearing mice (<i>P</i> = 0.002). <i>In vitro</i> analysis demonstrated that myofibroblasts promoted cell proliferation, invasion, and epithelial‐mesenchymal transformation of HCC cells, whereas <i>Msi2</i> deletion in myofibroblasts reversed these effects. Mechanically, <i>Msi2</i> knockout decreased myofibroblast‐derived IL6 and IL11 secretion by inhibiting the ERK1/2 pathway, and thus attenuated the cancer stem cell promoting effect of myofibroblasts. Interestingly, we found that the simultaneous knockout of <i>Msi2</i> in myofibroblasts and knockdown of <i>Msi2</i> in HCC cells could not further attenuate the implanted HCC progression. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Myofibroblast‐specific <i>Msi2</i> knockout abrogated the tumor‐promoting function of myofibroblasts and inhibited HCC progression in mouse models. Targeting myofibroblast MSI2 expression may thus prove to be a therapeutic strategy for HCC treatment in the future. </p></section>
gastroenterology & hepatology